V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10175206 | 10069402 | 1.82 | 86 | Palliative (P) | 2019-12-02 | 2019-12-02 | Eribulin | 02 | N | DASATINIB | 101115525 |
| 10184510 | 10069407 | 1.51 | 94.9 | null | 2020-06-14 | 2020-07-07 | Doxorubicin + Olaratumab | 02 | null | CYTARABINE | 101551993 |
| 10186892 | 10069408 | 1.8 | 90.2 | null | null | 2018-08-20 | Durvalumab | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100272932 |
| 10189203 | 10069410 | 0 | 90 | 03 | 2021-08-22 | 2021-08-22 | OCTREOTIDE | 02 | N | AZACITIDINE + VENETOCLAX | 100076185 |
| 10193508 | 10069412 | 1.54 | 49.4 | Palliative (P) | 2019-10-04 | 2019-10-05 | BENDAMUSTINE | 02 | N | PEMETREXED | 100385003 |
| 10193984 | 10069413 | null | null | null | 2018-10-31 | 2018-11-13 | EC + DOCETAXEL | 1 | null | IPILIMUMAB | 100028567 |
| 10194595 | 10069414 | 1.73 | 47.4 | Palliative (P) | 2014-11-03 | 2019-11-27 | Carboplatin + Docetaxel | 02 | N | INTERFERON ALFA | 100647434 |
| 10208849 | 10069420 | 1.62 | 63.4 | Palliative (P) | 2021-08-15 | 2021-09-03 | Busulfan Oral | N | N | FEC | 100114234 |
| 10212602 | 10069421 | 1.64 | null | null | 2019-12-30 | 2019-12-30 | Carboplatin + Pembrolizumab + Pemetrexed | 02 | null | FCR | 100779482 |
| 10240488 | 10069425 | 1.62 | 82.9 | Curative (C) | 2019-10-19 | 2019-10-19 | Midostaurin | 02 | Y | ANAGRELIDE | 101791713 |
| 10240910 | 10069426 | null | 87 | Disease modification (D) | 2019-07-07 | 2019-07-16 | Cisplatin + Etoposide po&iv 3 day | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL | 101674103 |
| 10245092 | 10069428 | 1.65 | 78 | Palliative (P) | 2017-11-03 | 2017-11-03 | CYTARABINE + ETOPOSIDE | 02 | N | PACLITAXEL + PERTUZUMAB + TRASTUZUMAB | 100537325 |
| 10251295 | 10069430 | 1.71 | 86.8 | Adjuvant (A) | 2020-05-06 | 2020-06-10 | Tivozanib | 02 | N | DOXORUBICIN + OLARATUMAB | 100189616 |
| 10257267 | 10069431 | 1.94 | 51.4 | null | 2020-09-26 | 2020-10-04 | Pertuzumab (Maintenance) | 02 | null | PONATINIB | 101351999 |
| 10257579 | 10069432 | 1.68 | 75 | Palliative (P) | 2021-08-09 | 2021-08-14 | CHOP R - 21 days | 02 | N | CARBOPLATIN + CETUXIMAB + FU | 101654023 |
| 10258053 | 10069433 | 1.73 | 90 | null | 2021-09-02 | 2021-09-27 | Panitumumab | 02 | null | CYCLOPHOSPHAMIDE + OBINUTUZUMAB + VINCRISTINE | 101354123 |
| 10275478 | 10069435 | 1.7 | 94.6 | null | 2019-05-01 | 2019-05-01 | null | 02 | null | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE + TREOSULFAN | 101464786 |
| 10275881 | 10069436 | 1.39 | 0 | Palliative (P) | 2020-07-20 | 2021-04-04 | BENDAMUSTINE | 02 | N | ETOPOSIDE | 100035992 |
| 10277622 | 10069438 | 1.59 | 49.4 | Palliative (P) | 2022-01-18 | 2022-01-18 | null | 02 | N | EVEROLIMUS + EXEMESTANE | 100962482 |
| 10278046 | 10069439 | 1.68 | 93.2 | Palliative (P) | 2020-12-16 | 2022-05-23 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | null | N | MITOMYCIN INTRAVESICULAR | 100142657 |
| 10280266 | 10069440 | 1.81 | 97.8 | Curative (C) | 2016-07-10 | 2019-03-07 | Cytarabine Low Dose | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100528963 |
| 10280783 | 10069442 | 1.73 | 0 | null | 2017-08-22 | 2017-08-27 | CYCLOPHOSPHAMIDE + RITUXIMAB | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100115113 |
| 10281533 | 10069443 | 1.76 | 84.4 | Palliative (P) | 2020-06-13 | 2020-06-17 | Bevacizumab+Carbo+Pacliaxel | 02 | N | BCG | 100107109 |
| 10283968 | 10069444 | 1.66 | 78.5 | Palliative (P) | 2019-05-24 | 2019-05-29 | Irinotecan + Modified De Gramont | 02 | N | AML18 TRIAL | 100620638 |
| 10284652 | 10069445 | 1.81 | 40.5 | 03 | 2020-08-29 | 2020-10-11 | FEC 60 or 75 | 02 | N | TRASTUZUMAB EMTANSINE | 100409135 |
| 10285735 | 10069446 | null | null | null | 2019-06-27 | 2019-12-29 | MPT | 02 | null | CARDAMON TRIAL | 100919886 |
| 10289946 | 10069449 | 1.68 | null | Palliative (P) | 2017-09-25 | 2020-07-15 | FLUOROURACIL + Panitumumab | Y | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + PROCARBAZINE + VINCRISTINE | 100434061 |
| 10292499 | 10069450 | 1.65 | 69.9 | Palliative (P) | 2019-10-07 | 2019-10-10 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 101851387 |
| 10293663 | 10069451 | 1.72 | 82.3 | null | 2021-02-18 | 2021-02-25 | CHOP R - 21 days | 01 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB | 101641490 |
| 10295481 | 10069452 | 1.54 | 71 | Palliative (P) | 2021-05-23 | 2021-06-19 | null | 02 | N | ERIBULIN | 101825217 |
| 10296424 | 10069453 | 0 | 80 | null | 2021-01-18 | 2021-10-19 | ETOPOSIDE | N | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 100068559 |
| 10296487 | 10069454 | 1.86 | null | Palliative (P) | null | 2018-05-13 | Erlotinib | 02 | N | DOXORUBICIN + OLARATUMAB | 100596748 |
| 10296794 | 10069455 | 1.86 | 46.7 | Palliative (P) | 2020-06-06 | 2021-07-19 | Cisplatin + Pemetrexed | 02 | N | CARBOPLATIN + FLUOROURACIL | 100794867 |
| 10297559 | 10069456 | null | 80 | 03 | 2020-06-01 | 2020-06-08 | CYCLOPHOSPHAMIDE + THALIDOMIDE | 02 | N | CISPLATIN + PEMETREXED | 100394923 |
| 10298584 | 10069459 | 1.6 | 61.8 | null | 2022-04-27 | 2022-05-10 | null | 02 | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101166478 |
| 10299345 | 10069460 | 1.86 | 73.4 | null | 2022-03-07 | 2022-03-07 | BLEOMYCIN | null | null | IDELALISIB | 100047422 |
| 10302602 | 10069463 | 1.82 | 77 | Adjuvant (A) | 2019-08-20 | 2019-09-04 | Cape+Cisplatin+Trastuzumab Main | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 100733846 |
| 10304540 | 10069465 | 1.77 | 73 | 03 | 2020-05-25 | 2020-05-25 | ATG + Busulfan + Fludarabine | 01 | N | EVEROLIMUS | 101609384 |
| 10306923 | 10069467 | 1.58 | 77.4 | Adjuvant (A) | 2020-09-08 | 2020-09-15 | Thalidomide 50mg | null | N | DA | 101407948 |
| 10307271 | 10069468 | 0 | 78.1 | Palliative (P) | 2019-03-17 | 2019-03-27 | MPT | 01 | N | IRINOTECAN + MDG | 100694388 |
| 10308206 | 10069469 | 1.69 | 52.6 | null | 2018-12-23 | 2019-01-21 | Doxorubicin + Olaratumab | 02 | null | CVD | 101841523 |
| 10336205 | 10069474 | 1.53 | 55.5 | Palliative (P) | null | 2020-07-08 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 101294257 |
| 10337274 | 10069476 | null | null | Disease modification (D) | 2019-08-07 | 2019-11-19 | EVEROLIMUS | 02 | N | AZACITIDINE + VENETOCLAX | 100832100 |
| 10341785 | 10069479 | 1.79 | 65.6 | null | 2020-06-01 | 2020-06-01 | CLARITY Trial | 02 | null | DOXORUBICIN + OLARATUMAB | 100988540 |
| 10347171 | 10069485 | 0 | 63.5 | Curative (C) | 2019-05-20 | 2019-05-22 | Cisplatin + Pemetrexed | 02 | N | BINIMETINIB + ENCORAFENIB | 101200589 |
| 10348373 | 10069488 | 1.86 | 77.8 | null | 2020-12-19 | 2021-01-13 | Lomustine | 02 | null | MITOXANTRONE | 101246639 |
| 10348886 | 10069490 | 1.7 | 98.7 | null | 2022-02-18 | 2022-02-18 | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 99 | null | CARMUSTINE + CYTARABINE + ETOPOSIDE + MELPHALAN | 101262326 |
| 10349385 | 10069491 | 1.44 | 59 | 03 | 2020-09-05 | 2020-09-05 | Eribulin | 02 | N | EVEROLIMUS | 100377680 |
| 10360895 | 10069496 | 1.75 | 98 | Curative (C) | 2018-07-12 | 2018-08-30 | PLATFORM Trial | 02 | N | CISPLATIN + FLUOROURACIL | 101609114 |
| 10362044 | 10069498 | 1.83 | 93 | Palliative (P) | null | 2019-09-01 | LOPP | 02 | null | BCG | 101165589 |